BIPROGY Inc. Just Missed EPS By 27%: Here's What Analysts Think Will Happen Next

The analysts might have been a bit too bullish on BIPROGY Inc. (TSE:8056), given that the company fell short of expectations when it released its half-yearly results last week. Results showed a clear earnings miss, with JP¥201b revenue coming in 9.6% lower than what the analystsexpected. Statutory earnings per share (EPS) of JP¥68.99 missed the mark badly, arriving some 27% below what was expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the current consensus from BIPROGY's nine analysts is for revenues of JP¥473.4b in 2027. This would reflect a meaningful 10% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to swell 18% to JP¥331. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥473.4b and earnings per share (EPS) of JP¥331 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

View our latest analysis for BIPROGY

The analysts reconfirmed their price target of JP¥5,356, showing that the business is executing well and in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on BIPROGY, with the most bullish analyst valuing it at JP¥6,500 and the most bearish at JP¥4,600 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await BIPROGY shareholders.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that BIPROGY's rate of growth is expected to accelerate meaningfully, with the forecast 21% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 7.5% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 6.6% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect BIPROGY to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for BIPROGY going out to 2029, and you can see them free on our platform here..

Plus, you should also learn about the 1 warning sign we've spotted with BIPROGY .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.